Replies to post #77411 on Biotech Values

[srsmgja]

I am offering an explanation for the flat sales growth because I see Tysabri's growth re-acelerating over the next number of quarters.

If I am correct, the market will reward ELN/BIIB because most of the market does not expect this to occur. If I am wrong (a very real possibility) then ELN/BIIB will not be rewarded.